AD-021.32 is a potent and selective inhibitor of the Janus kinase (JAK) family, currently under investigation in clinical trials for the treatment of autoimmune conditions such as rheumatoid arthritis… Read more
AD-021.32 is a potent and selective inhibitor of the Janus kinase (JAK) family, currently under investigation in clinical trials for the treatment of autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus by effectively blocking specific cytokine signaling pathways. This category provides access to high-quality reference standards essential for rigorous analytical testing and quality control of this active pharmaceutical ingredient. Laboratories utilize these compounds, including racemic mixtures, deuterated isotopologues, and the N-nitroso metabolite, to support critical procedures such as impurity profiling, metabolic stability studies, and quantitative bioanalysis. By incorporating these stable isotope labelled compounds and related analytical standards into method development and validation workflows, researchers can ensure accurate identification and quantification of impurities and metabolites throughout the drug development lifecycle of the pharmaceutical formulation.